AbbVie Inc. (ABBV)
| Market Cap | 395.38B |
| Revenue (ttm) | 59.64B |
| Net Income (ttm) | 2.35B |
| Shares Out | 1.77B |
| EPS (ttm) | 1.32 |
| PE Ratio | 169.40 |
| Forward PE | 16.24 |
| Dividend | $6.92 (3.09%) |
| Ex-Dividend Date | Jan 16, 2026 |
| Volume | 1,249,175 |
| Open | 219.00 |
| Previous Close | 218.71 |
| Day's Range | 219.00 - 223.62 |
| 52-Week Range | 163.81 - 244.81 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 236.47 (+5.7%) |
| Earnings Date | Oct 31, 2025 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $236.47, which is an increase of 5.70% from the latest price.
News
Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer
AbbVie's and Pfizer's Q3 earnings and dividend updates prompt a rating upgrade to Hold for ABBV and reiteration of Sell for PFE. PFE's higher yield (almost 7%) and single-digit P/E (FY1 P/E is ~8x onl...
ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November
This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. The pattern of modest dividend increases continues, with o...
Best Dividend Aristocrats For November 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed SPY in 2025, with a 6.27% YTD gain versus SPY's 17.8%. Despite overall underperformance, select Aristocrats like CAT, CAH, CHRW...
AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript
AbbVie Inc. ( ABBV) Q3 2025 Earnings Call October 31, 2025 9:00 AM EDT Company Participants Elizabeth Shea - Senior Vice President of Investor Relations Robert Michael - CEO & Chairman of the Board J...
AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend
AbbVie Inc. (NYSE:ABBV) reported third-quarter 2025 sales of $15.78 billion on Friday, beating the consensus of $15.59 billion.
AbbVie: Why Q3 Confirms Its Immunology Dominance
AbbVie Inc., 2 hours ago, published monstrous results for Q3, once again strengthening my confidence that it is a "powerhouse" in the autoimmune disease drugs market. Net revenues from AbbVie's immuno...
AbbVie Lifts Profit Outlook as Sales Rise
AbbVie raised its full-year adjusted earnings outlook, even though profit was pressured by increased expenses during the third quarter.
AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings.
Revenue attributed to AbbVie's oncology and aesthetics portfolio declined in the quarter.
AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs
AbbVie raised its 2025 profit forecast on Friday, after strong sales of newer immunology drugs Skyrizi and Rinvoq helped boost third-quarter results above Wall Street estimates.
AbbVie Reports Third-Quarter 2025 Financial Results
Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Percent; Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Percent; These Results Include an Unfavorable Impact of $1.50 ...
The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year
Allergan Aesthetics gives patients exciting BOTOX® Cosmetic offers only in the Allē app Buy one $50 gift card, get one free, plus, register, book a consultation, and get treated for a chance to win $2...
AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
In two replicate Phase 3 studies, upadacitinib (RINVOQ ®) achieved the co-primary endpoints of 50% reduction in Total Vitiligo Area Scoring Index (T-VASI 50) from baseline and 75% reduction in Facial...
Best Dividend Kings: October 2025
Dividend Kings are underperforming SPY in 2025, with a year-to-date return gap of 13.10%, but 12 Kings remain ahead of the index. Top performers include NFG, JNJ, ABBV, MO, FTS, ADM, NUE, GRC, NWN, PH...
AbbVie: Deep Discount Before Earnings
AbbVie Inc. is reiterated as a Strong Buy ahead of Q3 earnings, with revenue growth expected to outpace the sector median. ABBV consistently delivers double beats, maintains robust FCF margins, and is...
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
Final Trades: Abbvie, Qualcomm, Aptiv, and Palo Alto Networks
The Investment Committee give you their top stocks to watch for the second half.
The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients
Each winner will be awarded a $20,000 grant to fuel their businesses. Since the program's inception, BOTOX® Cosmetic has awarded more than $1 million in grants to The Confidence Project entrepreneurs.
AbbVie's Rinvoq shows superiority over Humira in head-to-head study
AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira, meeting the main goal of a head-to-head trial.
RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
Upadacitinib demonstrated superiority versus adalimumab for primary endpoint of achieving low disease activity (DAS28-CRP≤3.2) and ranked secondary endpoint of remission (DAS28-CRP
AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition
AbbVie earns a Strong Buy rating in my book, driven by Rinvoq's label expansions and robust immunology pipeline growth. ABBV achieved FDA approval for Rinvoq in giant cell arteritis and reported stron...
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). NORT...
Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending
The Investment Committee give you their top stocks to watch for the second half.
U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
- Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisa...
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie's growing ADC portfolio designed to target difficult-to-trea...